SYDNEY, July 20, 2026, 10:08 AEST.
- The stock ended Friday at A$3.20, falling 15.6%.
- Initial assessment indicates around A$354 million in equity value was lost.
- The U.S. legislation approves US$25 million and is still in committee.
4DMedical Ltd ASX:4DX opened Monday’s trading following a 15.6% drop on Friday. Initial calculations suggest the decrease in market value is approximately A$354 million.
The loss equaled 9.9 times the full Australian-dollar authorization of the bill. This serves as the main investor benchmark. The bill has secured bipartisan support, but no contracted revenue so far.
The ASX cash market began trading at 10:08 AEST. Public feeds with a delay continued displaying Friday’s A$3.20 closing price, so Monday’s price movement remained unconfirmed.
H.R. 9666 seeks to require the Department of Veterans Affairs to launch a lung-imaging pilot program running five years. The proposal has not become law and is currently before the House Veterans’ Affairs Committee.
| Metric | Figure |
|---|---|
| Friday last price | A$3.20 |
| Friday’s drop | 15.6% |
| Initial equity wiped out | A$354 million |
| Total authorized funding | US$25 million, or approximately A$35.8 million |
| Equity loss to authorization ratio | 9.9 times |
Figures are based on 599.64 million shares and Friday’s RBA exchange rate. The exchange rate stood at US$0.6980 for each Australian dollar.
Shares traded totaled 13.7 million, nearly double the average shown on Google Finance. The S&P/ASX 200 slipped 0.5% on Friday.
Shares of imaging software company Pro Medicus Ltd ASX:PME dropped 3.46%. The decline points to stock-specific selling instead of a broader market trend.
The bill as proposed permits funding of US$5 million per fiscal year between 2027 and 2031, amounting to US$25 million in total.
4DMedical referred to the initiative as a US$20 million pilot in its ASX announcement. Chief Executive Andreas Fouras said the plan marked “a landmark step” for veterans’ respiratory care. GovInfo
Neither number reflects booked revenue. According to Senate guidance, an authorization of appropriations provides direction for later funding actions on discretionary programs. The bill does not specify a vendor.
A separate concern lies with the eligibility section. The legislation stipulates software must be “approved” by the U.S. Food and Drug Administration. According to FDA data, XV LVAS was granted 510(k) clearance in May 2020. GovInfo
The FDA makes a clear distinction between 510(k) clearance and premarket approval. 4DMedical asserts that XV LVAS aligns with the definition outlined in the bill. However, the wording does not provide a definitive answer.
Risks: The bill could stall, and subsequent appropriations may not proceed. The VA might select a different qualified developer. The discrepancy in wording increases procurement uncertainty.
Investors are monitoring committee developments and any updates regarding the US$20 million-US$25 million gap. Confirmation of a VA lease would serve as the next concrete evidence. For now, political dynamics continue to be the driving force.
